Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Day One Biopharmaceutical (NASDAQ:DAWN) and maintains a $33 price target.
June 19, 2024 | 9:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Day One Biopharmaceutical and maintains a $33 price target.
The reiteration of a Buy rating and the maintenance of a $33 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100